NCT05672251
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +20 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
Clinical trial condition
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Explore clinical trials studying Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma. Study availability and eligibility vary by location and protocol.
6 public trials
2 recruiting studies
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma trial results
Recruiting
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
NCT05077527
- Conditions
- AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, Blood-Borne Infections, +36 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- University of Illinois at Chicago Chicago, Illinois, United States
- Memorial Sloan Kettering Cancer Center New York, United States
- Montefiore Medical Center - Moses Campus The Bronx, New York, United States
NCT04432506
- Conditions
- Hematologic Diseases, Hematologic Neoplasms, Hematopoietic and Lymphoid Cell Neoplasm, +20 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
NCT05821088
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +30 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, Not Recruiting
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
NCT05025800
- Conditions
- Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, +31 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
NCT05202782
- Conditions
- Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Hemic and Lymphatic Diseases, +27 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
- Medical College of Wisconsin Milwaukee, Wisconsin, United States